JOHN KIRKWOOD to Drug-Related Side Effects and Adverse Reactions
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Drug-Related Side Effects and Adverse Reactions.
Connection Strength
0.745
-
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
Score: 0.531
-
Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
Score: 0.125
-
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol. 2013 Apr; 24(4):1112-9.
Score: 0.074
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
Score: 0.014